eligibility_summary
Eligibility: Adults with histologically confirmed PDAC, AJCC T1–T3 N0–N2 M0, R0/R1 resection, no evidence of disease, CA19‑9 checked, 6–12 weeks post‑op, recovered with adequate labs, fit for atezolizumab, autogene cevumeran, and mFOLFIRINOX, contraception required. Exclude prior adjuvant/neoadjuvant/induction therapy, planned extra adjuvant therapy, splenectomy, ≥Grade 2 neuropathy or diarrhea, DPD deficiency or DPD‑inhibitors, autoimmune/immune deficiency, pregnancy/breastfeeding, strong CYP3A4/UGT1A1 modulators.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II randomized study in resected PDAC comparing adjuvant autogene cevumeran + atezolizumab + mFOLFIRINOX vs mFOLFIRINOX. Autogene cevumeran: individualized IV mRNA cancer vaccine encoding patient-specific neoantigens, taken up by dendritic cells to drive antigen presentation and prime/expand tumor-specific CD8/CD4 T cells (immunotherapy). Atezolizumab: anti-PD-L1 monoclonal antibody checkpoint inhibitor blocking PD-L1/PD-1 signaling to restore T-cell activity. mFOLFIRINOX chemotherapies: 5-FU (antimetabolite inhibiting thymidylate synthase), leucovorin (folate modulator enhancing 5-FU), irinotecan (topoisomerase I inhibitor), oxaliplatin (DNA-crosslinking platinum). Targets/pathways: dendritic cells, T-cell activation, PD-L1 axis, tumor DNA synthesis/repair and replication.